


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Makoto KAIBARA et al

Appln. No : 10/733,288

Filed : December 12, 2003



Group Art Unit : 1644

Examiner : Szperka

For : BLOOD COAGULATION FACTOR-ACTIVATING PROTEIN AND ANTIBODY
THERETO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria VA 22314

Sir :

Further to the Information Disclosure Statement filed March 12, 2004, and in accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner.

Hideki TAKAHASHI et al., "Structure of the Human Neutrophil Elastase Gene", The Journal of Biological Chemistry, Vol. 263, No. 29, pp. 14739-14747 (1988);

Hideki TAKAHASHI et al., "Myelomonocytic Cell Lineage Expression of the Neutrophil Elastase Gene", The Journal of Biological Chemistry, Vol. 263, No. 5, pp. 2543-2547 (1988); and


S. SINHA et al., "Primary Structure of Human Neutrophil Elastase", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 2228-2232 (April 1987).

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that this disclosure statement is being filed after first action on the merits, but prior to issuance of an office action closing prosecution. Therefore, a check including the amount of \$180.00 is enclosed. However, if the fee is deficient and/or if any additional fee is required for consideration of this disclosure statement, including any fee under 37 C.F.R. 1.17(p), Applicants hereby authorize that any required fee be charged to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,
Makoto KAIBARA et al.


Bruce H. Bernstein
Reg. No. 29,027

August 26, 2005
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Arnold Turk
Reg. No. 33,094

Application No.
10/733,288

Group
1644

U.S. PATENT DOCUMENTS

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P24684	Serial No. 10/733,288
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Makoto KAIBARA et al.	
		Filing Date December 12, 2003	Group 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 1 8 0 8 1 9	01/1993	CAYRE			
	5 9 6 8 7 8 2	10/1999	STEVENS			
	6 2 3 2 4 5 6	05/2001	COHEN et al.			
	6 2 7 7 6 1 8	08/21/01	KOPETZKI et al.			
	6 3 4 2 5 8 5	01/29/02	GROSSMANN			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
0 0 / 1 7 6 5 8	03/30/00	W.I.P.O.			
9 7 / 4 7 7 3 7	12/18/97	W.I.P.O.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	KAWAKAMI et al., <u>Biorheology</u> , Vol. 32, No. 5, pp. 521-536 (1995).
2	KAIBARA et al., Frontier Research on Circulation System Dynamics (report on research performed under a grant from the Science and Technology Agency, 1998), edited by Okayama New Technology Promotion Foundation, pp. 43-54 (1999).
3	KÖHLER et al., <u>Nature</u> , Vol. 256, pp. 495-497 (1975).
4	MASUTANI et al., <u>Nature</u> , Vol. 399, No. 6737, pp. 700-704 (1999).
5	KAIBARA et al., <u>Biorheology</u> , Vol. 22, No. 3, pp. 197-208 (1985).
6	KAIBARA et al., <u>Colloids and Surfaces B: Biointerfaces</u> , 19, pp. 209-217 (2000).
7	SAKAMOTO et al., <u>Medical Engineering and Bioengineering</u> , Vol. 16, pp. 45-52 (1978)
8	FUJII et al., <u>47th Rheology Forum Abstracts</u> , pp. 295-296 (1999).
9	ANDERSSEN et al., <u>Thrombosis and Haemostasis</u> , 70, (3), pp. 414-417 (1993).
1 0	KAWAMATA et al., <u>Intensive Care Med.</u> , 21, pp. 443-446 (1995).
1 1	NAKAMURA et al., "Protein Structure", <u>Molecular Biology of the Cell</u> , No. 1, pp. 111-127 (1985).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT
 PATENT APPLICANT

(Use several sheets if necessary)

U.S. Department of Commerce
 Patent and Trademark Office

Atty. Docket No.
 P24684

Serial No.
 10/733,288

Applicant
 Makoto KAIBARA et al.

Filing Date
 December 12, 2003

Group
 1614

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	2	ERNST, <u>Journal des Maladies Vasculaires</u> , 17, pp. 93-96 (1992).					
	1	3	MAMMEN, <u>Chest</u> , 102, 6, pp. 640S-644S (1992).					
	1	4	CHIEN, <u>Science</u> , Vol. 168, pp. 977-979 (1970).					
	1	5	YASAKA et al., <u>J. Heart Valve Dis.</u> , Vol. 2, pp. 25-34 (1993).					
	1	6	KAIBARA et al., <u>Am. J. Obstet. Gynecol.</u> , Vol. 180, No. 2, Part 1, pp. 402-405 (1999).					
	1	7	LUPU et al., <u>Thrombosis and Haemostasis</u> , 70, (4), pp. 579-583 (1993).					
	1	8	Narayanam V. RAO et al., "Characterization of Proteinase-3 (PR-3), a Neutrophil Serine Proteinase", <u>The Journal of Biological Chemistry</u> , Vol. 266, No. 15, pp. 9540-9548 (1991).					
	1	9	Imamura et al. <u>Biochem J.</u> , (2001) 353:325-331.					
	2	0	Kenneth A. BAUER et al., "Factor IX is Activated In VIVO by the Tissue Factor Mechanism", <u>Blood</u> , Vol. 76, No. 4, pp. 731-736 (1990).					
	2	1	S. KAWAKAMI et al., "Rheological Approach to the Analysis of Blood Coagulation in Endothelial Cell-Coated Tubes: Activation of the Intrinsic Reaction on the Erythrocyte Surface", <u>Biorheology</u> , Vol. 32, No. 5, pp. 521-536 (1995).					
	2	2	G. SARKAR et al., "Direct Sequencing of the Activation Peptide and the Catalytic Domain of the Factor IX Gene in Six Species", <u>Genomics</u> , Vol. 6, pp. 133-143 (1990).					
	2	3	Masahiro YAMAMOTO, "Effects of Fibrinogen, Globulin, Albumin and Hematocrit on the Kinetics of Erythrocyte Aggregation in Man", <u>Angiology</u> , Vol. 37, No. 9, pp. 663-671 (1986).					
	2	4	M. KAIBARA et al., "S22-I Factor IX Activation by Erythrocyte Membranes is a Powerful Trigger for Thrombus Formation Under Stagnant Flow Conditions", <u>Biorheology</u> , Vol. 39, No. 5, pp. 654 (2002).					

COPY

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.